A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.
Inclusion Criteria:
Exclusion Criteria:
Evanston, Illinois 60201, United States
Berazategui, Buenos Aires, 1884, Argentina
Rosario, Santa FE, 2000, Argentina
Rosario, Santa FE, 2000, Argentina
Miskolc, Borsod-Abauj Zemplen county 3529, Hungary
Budapest XII, Budapest 1122, Hungary
Kékesteto, 3233, Hungary
Kurume-shi, Fukuoka 830-0011, Japan
Osaka-sayama-shi, Osaka 589-8511, Japan
Chuo-ku, Tokyo 104-0045, Japan
Koto-ku, Tokyo 135-8550, Japan
Ube-shi, Yamaguchi 755-0241, Japan
Wellington, 6021, New Zealand
Moscow, Moscow 115478, Russia
Yekaterinburg, Sverdlovsk Oblast 620043, Russia
Murmansk, 183047, Russia
Dalin Township, 622, Taiwan
Gwent, NP20 2UB, United Kingdom
Newcastle upon Tyne, NE7 7DN, United Kingdom